TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00009217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol-Haloperidol
Description: Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol-Placebo
Description: Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
Study: NCT04501679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as SC injection.
Study: NCT04922749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MULTI+
Description: MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
Study: NCT04255836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
Study: NCT00939419

Intervention type: OTHER
Group type: OTHER
Intervention: Health workers TB care group
Description: Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
Study: NCT04255836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the first line chemotherapy for metastatic NSCLC
Description: paclitaxel+carboplatin or pemetrexed+cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: SBRT total doses of 50-60Gy/≤10F
Study: NCT04761029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RIIS
Description: unilateral Rhomboid intercostal and subserratus block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: intravenous patient-controlled analgesia (tramadol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: intravenous patient-controlled analgesia (tramadol)
Study: NCT02742350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT - POWERbreathe Plus Light Resistance®, SP, BR
Description: POWERbreathe Plus Light Resistance®, SP, BR
Study: NCT00510224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin
Description: Sandostatin 30mg intramuscular every 28 days
Study: NCT04958616

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test.
Description: Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test.
Description: Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
Study: NCT02509494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
Study: NCT00939419

Intervention type: OTHER
Group type: OTHER
Intervention: Community health workers TB care group
Description: Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered treatment group
Description: Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
Study: NCT01340261

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
Study: NCT03926884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Three-seeds mixture
Description: mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
Study: NCT00251641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
Study: NCT02135120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal epidural anesthesia technique with intrathecal morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
Study: NCT02110017

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI social cognition task
Description: fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI social cognition task
Description: fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
Study: NCT01976013

Intervention type: DEVICE
Group type: OTHER
Intervention: Coaguchek
Description: The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
Study: NCT03926884

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: warm water with negligible amount of the three-seeds mixture
Study: NCT01153451

Intervention type: OTHER
Group type: OTHER
Intervention: Email Notification
Description: BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
Study: NCT02488980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Description: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for three days followed by placebo once a week for 24 weeks
Study: NCT03003637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
Study: NCT02174393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal Peel
Description: Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Microneedling Skin Care
Description: On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Universal Peel Skin Care
Description: * Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening
Study: NCT02468297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Acupunture Shoes
Description: Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
Study: NCT04291807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video education
Description: Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
Study: NCT00632086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin component of PA32540
Description: The 325 mg aspirin component of PA32540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ecotrin
Description: 325 mg Ecotrin
Study: NCT00379990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: 60 mg /day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7.5 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03260075

Intervention type: OTHER
Intervention: cat
Description: Cat living at the ward
Study: NCT03745131

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw to obtain serum to determine anti-orthopox antibody titres.

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw to obtain serum to determine anti-orthopox antibody titres.

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw to obtain serum to determine anti-orthopox antibody titres.
Study: NCT02509494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for injection.
Study: NCT00423085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
Study: NCT02614313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open breath test with fructose
Description: Open randomised fructose 35g during breath test

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Breath test with sweet placebo (Assugrin)
Description: Double-blind randomised breath-testing with sweet placebo (Assugrin)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Breath test with neutral placebo (still water)
Description: Double-blind randomised breath-testing with neutral placebo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded breath test with fructose
Description: Double-blind randomised fructose 35g during breath test
Study: NCT00734734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: 1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
Study: NCT01218789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO daily for 1 year
Study: NCT02344407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSVG-ZEBOV
Description: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-EBO Z
Description: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01070602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior (more central) corneal paracentesis incision
Description: 3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
Study: NCT00213252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast plus prednisolone
Description: Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Six daily doses of oral prednisolone
Study: NCT00407914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamid
Description: Subcutaneous injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Injection in dermis
Study: NCT01238315

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HuCNS-SC
Description: Surgery to implant human CNS stem cells
Study: NCT02507193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation
Description: An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermedullary Nail
Description: An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
Study: NCT04032171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received evobrutinib twice daily (BID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Participants received avonex® IM injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex® matched Placebo
Description: Participants received IM injection of placebo matched to avonex® once a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evobrutinib matched Placebo
Description: Participants received placebo matched to evobrutinib twice a day.
Study: NCT02295735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Border Sacrum and Mepilex® Border Heel
Study: NCT03007017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor nephrectomy, prior to cross clamp of donor aorta
Description: The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deceased donor nephrectomy, standard of care
Description: The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
Study: NCT03147339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGEs restricted diet
Description: Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
Study: NCT02565771

Intervention type: OTHER
Intervention: Adapted physical activity
Description: The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
Study: NCT02913222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Comparison of two rehabilitation approaches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Comparison of two rehabilitation approaches
Study: NCT02776410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumer reactions to tailored messages sent via app
Description: The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.